Kang Yuan, Kang Yixin, Zhang Dianbao, Yao Jun
The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, China.
Front Immunol. 2024 Dec 3;15:1460533. doi: 10.3389/fimmu.2024.1460533. eCollection 2024.
Antiangiogenic therapy can alter the tumor microenvironment (TME) and thus exert anti-tumor effects, and has the potential to increase the efficacy of conventional therapy and immunotherapy. The aim of this study was to examine current research hotspots and collaborative networks on the relationship between previous antiangiogenic therapies and the TME through bibliometric analysis.
From the Web of Science Core Collection database, all publications from inception through December 2023 were downloaded. In-depth analysis was performed by Bibliometrix packages in R. Keywords and collaborative networks were analyzed using VOSviewers and Citespace.
We obtained a total of 9027 publications. They come from 27 countries and were published in 1387 journals, with a total of 39,604 authors in the studied area. The number of publications increases dramatically from 2014 to 2023, accounting for 73.87% (6668/9027) of all publications. China and CANCERS have the highest number of publications on this topic and CANCER RESEACH is the most influential. In the last decade (2013- 2023), research has gradually shifted from studying the role of vascular endothelial growth factor in the TME to examining how antivascular therapy can contribute to the progression of cancer treatment. Furthermore, nanoparticle-based drug delivery systems and immunotherapy have been widely explored in the past five years. The findings of this study will help scientists to explore this promising field in depth by providing insight into the relationship between antiangiogenic therapy and the TME.
The relationship between the antiangiogenic therapy and the TME has been developing rapidly, but cooperation between different institutions and countries is still limited. Researchers can use this study to identify hotspots and develop trends for related research, thereby facilitating the development and cooperative exchange in this field, as well as to suggest potential future research directions.
抗血管生成疗法可改变肿瘤微环境(TME),从而发挥抗肿瘤作用,并有可能提高传统疗法和免疫疗法的疗效。本研究旨在通过文献计量分析,探讨以往抗血管生成疗法与TME关系的当前研究热点和合作网络。
从Web of Science核心合集数据库中下载自数据库建立至2023年12月的所有出版物。使用R语言中的Bibliometrix软件包进行深入分析。使用VOSviewer和Citespace分析关键词和合作网络。
我们共获得9027篇出版物。它们来自27个国家,发表在1387种期刊上,该研究领域共有39604位作者。2014年至2023年出版物数量急剧增加,占所有出版物的73.87%(6668/9027)。中国和《Cancers》在该主题上的出版物数量最多,《Cancer Research》最具影响力。在过去十年(2013 - 2023年)中,研究逐渐从研究血管内皮生长因子在TME中的作用,转向研究抗血管疗法如何促进癌症治疗的进展。此外,基于纳米颗粒的药物递送系统和免疫疗法在过去五年中得到了广泛探索。本研究结果将有助于科学家深入探索这一有前景的领域,为抗血管生成疗法与TME之间的关系提供见解。
抗血管生成疗法与TME之间的关系发展迅速,但不同机构和国家之间的合作仍然有限。研究人员可以利用本研究确定相关研究的热点和发展趋势,从而促进该领域的发展与合作交流,并提出潜在的未来研究方向。